In Brief: NDAC
This article was originally published in The Tan Sheet
NDAC: Acting Executive Secretary for FDA's Nonprescription Drugs Advisory Committee is Rhonda Stover, currently the exec sec for the Anti-Viral Drugs and Psychopharmacologic Drugs Advisory Committees. Former exec sec Andrea Neal has left the position to work on the agency's implementation of the new adverse event reporting system. Kathleen Reedy, exec sec for the Arthritis Drugs and the Endocrinologic and Metabolic Drugs Advisory Committees, will oversee NDAC's Dental Plaque Subcommittee until a replacement is named. The post has been advertised and is expected to be filled in about six weeks, according to the agency...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC